BofA lowered the firm’s price target on GoodRx (GDRX) to $4.25 from $4.50 and keeps an Underperform rating on the shares after the company ...

KeyBanc lowered the firm’s price target on GoodRx (GDRX) to $6 from $7 and keeps an Overweight rating on the shares. The firm notes healthcare ...

GoodRx (NASDAQ:GDRX – Free Report) had its price objective reduced by Citigroup from $7.00 to $6.25 in a research note issued ...

GoodRx CEO Wendy Barnes outlined the company's priorities at the 2025 JP Morgan Healthcare Conference in San Francisco.

Shares of GoodRx have fallen ~20% over the past year. Amid hopes for growth via direct relationships with pharmaceutical manufacturers, the company may have hit a near-term bottom. GDRX returned ...

GoodRx Holdings, Inc. (NASDAQ:GDRX – Get Free Report) dropped 8.4% during trading on Monday after Citigroup lowered their price target on the stock from $7.00 to $6.25. Citigroup currently has a buy ...

Goodrx Holdings Inc (GDRX) stock saw a modest uptick, ending the day at $4.57 which represents a slight increase of $0.15 or 3.39% from the prior close of $4.42. The stock opened at $4.41 and touched ...

During the last three months, 4 analysts shared their evaluations of GoodRx Holdings GDRX, revealing diverse outlooks from bullish to bearish. The following table provides a quick overview of ...